• Liang Lunuan, a medical student, was rejected for a job at Xiamen City Traditional Chinese Medicine Hospital despite topping both written and interview tests due to her Hashimoto's thyroiditis found during the medical examination.
• Liang sued the hospital for employment discrimination and violation of equal employment rights, but her lawsuit was dismissed by the Huli District Court in Xiamen, which ruled that the hospital's medical examination standards were legal and reasonable as they adhered to national guidelines for civil servant recruitment.
• The case highlights ongoing debates about the fairness and legality of physical examination standards used in public sector recruitment, with many arguing that these standards are outdated and discriminatory against individuals with chronic illnesses like Hashimoto's thyroiditis.

【本文系数据通用户提前专享】体检标准将报考公职甚至民营单位的慢性病患者拦在门外，引发就业公平的争论。当事人诉诸法律，几无胜算

体检标准将报考公职甚至民营单位的慢性病患者拦在门外，引发就业公平的争论。当事人诉诸法律，几无胜算

医药领域反腐政策继续落实，但头部企业销售费用继续增长；医药板块内中药不乏政策利好，集采在2023年对企业的影响较为微小；九成公司实现盈利的同时，有企业开始进行化药、生物药创新项目布局谋求转型

聚焦领域从2022年血液透析、高值医用耗材，2023年医学影像检查、临床检验和康复，扩展至今年的重症医学、麻醉、肺部肿瘤

4月22日—26日，A股医药生物板块累计上涨4.43%，港股恒生医疗保健指数、香港上市生物科技指数涨幅均超过11%

在2023年广东联盟集采中，艾迪注射液降价84.7%至18.27元/10ml，以成人每次用量50-100ml、30天一疗程计算，患者每疗程花费约2740元至5481元。该药品已进入省级医保和国家医保目录

必须尽快采取措施，改善检测与预防；虽然对乳腺癌的研究和治疗已有极大改善，但巨大的不平等现象仍然存在

集采影响进一步出清、创新药销售增长、持续控费，2023年实现营收228.20亿元。恒瑞医药2023年及今年第一季度，归母净利润均实现了10%的增长

推荐：禽流感首次在南极洲大规模传播；票房｜高评分电影扎堆 《白日之下》香港金像奖夺三奖

新加坡政府长期以来致力于打造生物医学科研生态系统，不仅带来了经济成果，而且促进了战略性商业伙伴关系的建立、人才的吸引和药物发现方面的创新突破

妇幼健康服务体系正在加速萎缩

海外业务逐步加深对医药板块估值的影响，一方面授权转让交易显著增长，工程师红利逐步显现，另一方面，主要出海地创新药品价格高于国内，对于医药企业的利润端有正向作用

自阿斯利康收购亘喜生物以来，中国创新药公司或被认为具有“中国血统”的创新药公司，被海外药企并购的态势开始升温

锦欣生殖的收益主要来自中国以及美国两大市场，在此番投资印尼辅助生殖医疗集团Morula之前，其业务范围虽已辐射至东南亚，但占比很小

• China's pharmaceutical industry has seen domestic new drugs benefit from price reductions due to mature national health insurance negotiation rules, but this has impacted corporate profits and investment in innovation. Dual reporting in China and the U.S. is becoming standard for companies developing innovative projects, with BeiGene's Zanubrutinib and Legend Biotech's Cilta-cel achieving significant sales in international markets.
• The National Healthcare Security Administration issued a draft aiming to encourage high-quality innovation by establishing a pricing mechanism for newly listed chemical drugs, requiring companies to submit a self-assessment form before declaring listing prices. This approach aims to prioritize genuine innovation and guide enterprises towards focusing on clinical value in drug development.
• Concerns exist about the impact of domestic drug price reductions on global pricing systems and the motivation for continued investment in innovation. The "Draft for Solicitation of Opinions" proposes quantitative rules for pricing innovative drugs, emphasizing clinical value but faces criticism regarding its potential interference with market economy principles and the autonomy of pharmaceutical companies in setting drug prices.

【本文系数据通用户提前专享】创新药定价机制牵一发动全身，甚至影响到全球药物市场

创新药定价机制牵一发动全身，甚至影响到全球药物市场

2023年，居民医保个人缴费标准涨至380元；前七个月到前十一个月，居民医保基金的累计支出都大于收入